Supplementary Information

Simulation session guide

Imperial College London

NAVIFY Clinical Trial Match evaluation - simulation session guide

Background

This is an independent study conducted by the team at the Institute of Global Health Innovation.

The NAVIFY Clinical Trial Match application is a digital solution that helps clinicians to match patients to clinical trials. The app is part of the NAVIFY Tumor Board solution, a solution used to present patient information during cancer multidisciplinary team (MDT) meetings.

NAVIFY Clinical Trial Match automatically searches a patient record using key criteria to identify trial matches (e.g., cancer type, stage, genomic alterations, etc.). Further information on how the app works is provided separately in the NAVIFY Clinical Trial Match User Guide.

At this stage of the product development, Roche would like to understand how NAVIFY Clinical Trial Match app could be implemented in UK healthcare settings and where it could be useful in clinical practice.

Purpose of today

The purpose of today is to evaluate the Clinical Trial Match app, including how it could improve the practice of screening patients for clinical trials, how relevant the search results are, and how easy it is to use compared to standard methods and tools.

Simulated Scenario

In this session, you will play a member of the clinical or research team at Imperial College Healthcare NHS Trust who is responsible for screening patients with lung cancer for clinical trials (e.g., Oncologist, Clinical Research Fellow, Research Nurse, Clinical Trial Practitioner, etc.).

Today you are preparing to meet with 10 patients in clinic and you have been tasked with finding a suitable, actively recruiting clinical trial (or trials) for each of them.

After a quick check, you and your team have already decided that none of the patients are eligible for your local portfolio trials and so you are searching for other trials nearby that might be suitable.

You will complete two separate trial matching exercises today (the order will be randomised):

- For five of these patients, you will only have access to the NAVIFY Clinical Trial Match app to identify suitable trials.
- For the five other patients, you will have access to other online search tools (ClinicalTrials.gov, ClinicalTrialsRegister.eu, NIHR's Portfolio Search website).

Imperial College London

You will have exactly 60 minutes for each exercise. During the trial matching exercise, you will be asked to record the suitable trials that you find on a worksheet.

Important assumptions for today's session

Regarding the patient cases:

- Please try and find the trial(s) you think would be most suitable for each patient given the clinical information at hand. There may be some investigations that have not been performed to make a final decision on enrolment. However, we would like you to focus on finding a potentially suitable trial rather than make any final decision on enrolment.
- Please assume that all patient information is accurate. The mock clinical details, pathology reports and radiology reports have been developed by experienced consultant oncologists, a histopathologist and a radiologist respectively.
- Please consider the imaging indicative of what you would have to hand in a real-life situation. For pragmatic reasons, the radiology imaging is in JPEG format (as opposed to full CT/MRI imaging).

Regarding NAVIFY:

- Please assume that NAVIFY Clinical Trial Match is already integrated with the electronic health records (EHR) system in your practice.
- Please assume that NAVIFY Clinical Trial Match is compliant with data protection, security
 and information governance requirements.

Regarding the simulation session:

 Throughout the session, the screen of the computer will be recorded to inform the research team's analysis. The recording will not be shared with anyone outside of the research team at Imperial College London.

Session outcome

We hope to gather your anonymous feedback regarding:

- How useful you think NAVIFY Clinical Trial Match app would be in your routine practice
- Where you think NAVIFY Clinical Trial Match app could make a difference in the screening methods and decision-making processes in UK healthcare settings
- The simulation methods we are using today to evaluate this software, including the patient cases, the guidance materials provided, and the general organisation and conduct of the session.

Guidance provided to participants before the start of the simulation session which outlines the clinical tasks to be simulated using the study materials provided, as well as assumptions to made throughout the session regarding the patient cases and NAVIFY CTM.

Example of a synthetic patient case including clinical summary, histopathology and radiology report

NHS

Imperial College Healthcare

CLINICAL DETAILS

BLOGGS, JOSEPH IGHI005 DoB 1/1/1956

64 yo Male

Diagnosis October 2019, stage IV (T3N2M1a; T3N2M1a (separate nodules) lung adenoCa

November 2019 1L Pembrolizumab monotherapy initially q3w then q6w with good tolerance

Best response SD Feb 2020

2/6/2020 CT TAP: oligoprogressive disease in RUL 30/6/2020 CT TAP: new liver metastasis (12mm + 16mm) – further progression in RUL (radiology input)

PS ECOG 1 ASA 2

ex smoker 35 pack-years

Bloods: unremarkable but ALT 59 TSH 6.2 T4 12

*this is a mock patient case prepared by a consultant oncologist for the purposes of

the simulation sessions conducted by the Institute of Global Health Innovation, Imperial College London

Clinical summary of one of the synthetic patient cases which was composed by a consultant thoracic oncologist and reverse-engineered to match to an existing lung cancer clinical trial identified by the research team at Imperial College London.



Imperial College Healthcare

HISTOPATHOLOGY REPORT

IGHI005/20 BLOGGS, JOSPEH

SPECIMEN(S) RECEIVED EBUS, 4R CLINICAL DATA Previous RUL segmentectomy. Enlarging non FDG avid UR lymph node MACROSCOPIC DESCRIPTION Pot labelled BLOGGS, JOE and left 4R: Numerous tangled and brown and cream cores of tissue altogether measuring 14 x 12 x 2mm, all taken in 1 cassette. (CQ) MICROSCOPIC DESCRIPTION EBUS tissue comprising blood with fragments of crushed lymphoid tissue. There are clusters of atypical cells representing metastatic carcinoma.

Immunohistochemistry shows these to be positive for TTF1 and negative for p40. This represents metastatic lung adenocarcinoma. HISTOLOGICAL DIAGNOSIS EBUS TBNA 4R: metastatic adenocarcinoma COMMENT Report requires urgent review ***Electronically Signed Out*** Dr.J Smith

SUPPLEMENTARY REPORT

PD-L1 (22C3, DAKO Pharm DX) IHC Report Sufficient for assessment – YES 100% of tumour cells expressing PD-L1 Intensity of staining by tumour cells: 3+ -80% 2+ - 20 % 1+ - 0 % 0 - 0 % Staining Pattern: Homogenous expression RESULT: STRONG POSITIVE (≥50% Expression) ***Electronically Signed Out*** Dr J Smith

SUPPLEMENTARY REPORT ALK is negative by immunohistochemistry. ROS1 is negative by immunohistochemistry. ***Electronically Signed Out*** Dr J Smith

*this is a mock patient case prepared by a consultant histopathologist for the purposes of the simulation sessions conducted by the Institute of Global Health Innovation, Imperial College London



Electronically Signed Out

Dr J Smith

Detected Variants

TP53 p.(Pro72Arg), c.215C>G, COSM250061 45% TP53 p.(Asp281Asn), c.841G>A, COSM43596 21%

Detected Copy Number Gains

No copy number gains detected in this sample.

Detected Gene Fusions

No assessed gene fusion events were detected in this sample.

Salient 'negative' findings: Please be aware that due to the very high numbers of variants assessed by this assay, only detected variants are reported. Nevertheless, for the avoidance of doubt in relation to those genes of most common therapeutic interest; unless specifically stated to the contrary above, no variants were detected in this specimen at the following loci: BRAF (Codon 600), EGFR (Codons 492, 719, 768, 790, 797, 858, 861, exon 19 deletions/insertions or exon 20 insertions), KRAS & NRAS (Codons 12, 13, 59, 61, 117 & 146), KIT (exons 9, 11, 13 & 17), MET (transcribed sequences with exon 14 'skipped').



*this is a mock patient case prepared by a consultant histopathologist for the purposes of the simulation sessions conducted by the Institute of Global Health Innovation, Imperial College London

Histology report for one of the synthetic patient cases which was developed by a consultant histopathologist and reverse-engineered to match to an existing lung cancer clinical trial identified by the research team at Imperial College London.

3



Imperial College Healthcare

IMAGING REPORT

BLOGGS, JOSPEH

IGHI005

RYJ20525263 02/06/2020

CT Chest/Abdomen/Pelvis with contrast

Clinical details:

The 64 yrl male. Diagnosis of T3 N1 M1a lung adenoca. Nov 2019 treated with Pembrolizumab monotherapy initially q3w then q6w with good tolerance. Follow up scan.

Report:

Contrast enhanced axial images of the chest abdomen and pelvis. Comparison is made with a previous CT scan of October 2019 and Feb 2020.

Chest

The previous right upper lobe mass demonstrates further reduction in size compared to the previous study and now measures 2.2 cm x 2.1 cm (previously 3.5 cmx 3 cm). The previously demonstrated ipsilateral pulmonary nodule is unchanged in size in appearance. No new nodules demonstrated.

The previously demonstrate mediastinal lymphadenopathy has slightly increased in size in maximum measuring some 1.2cm in short axis in the right hilum (previously 9mm) cm).

Abdomen/Pelvis

No focal hepatic lesions. The spleen, pancreas, adrenals, kidneys are unremarkable. No underlying bony lesions.

Comment:

The appearance are in keeping with oligoprogressive disease where the right upper lobe lesion has reduced in size and now measures 2.2x2.1 cm. There is however the increase in the size of the right ipsilateral hilar lymph node that there is a 1.4 cm in short axis.

*this is a mock patient case prepared by a consultant radiologist for the purposes of the simulation sessions conducted by the Institute of Global Health Innovation, Imperial College London



Imperial College Healthcare

IMAGING REPORT

BLOGGS, JOSPEH

IGHI005

RYJ20526266 30/06/2020 CT Chest/Abdomen/Pelvis with contrast

Clinical details: The 64 yrl male. Diagnosis of T3 N1 M1a lung adenoca. Nov 2019 treated with Pembrolizumab monotherapy initially q3w then q6w with good tolerance. Now has deranged ALT. ? mets

Report:

Contrast enhanced axial images of the chest abdomen and pelvis. Comparison is made with a previous CT scan of Feb 2020 and 2nd June 2020.

Chest

The previously demonstrated right upper lobe lesion has unfortunately increased in size and now measures $6.5 \text{ cm} \times 6.5 \text{ cm}$ (previously $4 \times 5 \text{ cm}$). There is evidence or some subsegmental atelectasis surrounding this lesion. There are two new ipsilateral lung nodules in the right upper lobe.

The right hilar lymph node is increased in size and now measures 2.5 cm short axis. Extensive lymphadenopathy is now demonstrated.

Abdomen/Pelvis

Since the previous scan there is now evidence of 2 new contrast enhancing lesions within the right and left hepatic lobe measuring 1.2 and 1.6 cm respectively. No evidence of abdominal or pelvic lymph node enlargement. The adrenals are unremarkable. The spleen, pancreas, gallbladder and kidneys are unremarkable. No evidence of bony lesions. The unprepared bowel is unremarkable.

Comment:

Appearances are in keeping with progressive disease with increase in the size of the right upper lobe lesion, increase in the size and extent of mediastinal lymphadenopathy. Two new hepatic lesions within the right and left lobes.

The clinician has been emailed with the findings

*this is a mock patient case prepared by a consultant radiologist for the purposes of the simulation sessions conducted by the Institute of Global Health Innovation, Imperial College London

Radiology reports for one of the synthetic patient cases which was developed by a consultant interventional radiologist and reverse-engineered to match to an existing lung cancer clinical trial identified by the research team at Imperial College London.

Screenshots of NAVIFY Clinical Trial Match application (v1.4) during the simulation sessions

TUMOR BOARDS PATIENTS	APPS		Q Imperial	Study Roche GE Healthca
Spring, Kathleen emale, 58 IRN IGH1010	CANCER INFO			Timeline
	PATIENT SUMMARY ①	TUMOR INFORMATION (1)		All Events
CANCER INFO	S8yo female Relapsed pT1c pN0 M0 adenoCa lung. EGFR WT, ALK/ROS1 neg, PDL-1 65%	TYPE LOCATION	Metastatic Adenocarcinoma Lung	Upcoming Event Past Events
Metastatic Adenocarcinoma	October 2018: RUL lobectomy (PL0 R0) with histology as above, good recovery and regular follow up Most recent follow up scan reveals relapsed disease in the thorax and patient had an EBUS			-2020 Histology Report Aug 14, 2020
PATIENT HISTORY	PS ECOG 0 ASA 1 Ex-smoker (ceased 22 y ago) with 20 pack-year Patient asymptomatic exempt for a mild cough, which she had before			•
Clinical Trial Match	after the operation CT TA: Disease recurrence with multiple soft pulmonary mets and right hilar lymphadenopathy, suggestive of stage IV disease (T4, N2, M1a) EBUS: pathology report			-2018 Surgery Oct 22, 2018 RUL lobectomy (PLO R0)
	STAGE () c 4 2 1a			

1) Overview of a patient record in NAVIFY Tumor Board, including a timeline of investigations and patient summary.

UMOR BOARDS PATIENTS	APPS	Q Impe	erial Study Roche	GE He
tel, Anushka nale, 81 N IGHI008				help & more
CANCER INFO ung idenocarcinoma	Clinical Trial Match		About this app App Launch Preferences	
c 2 0 0	Add Additional Search Terms		Help with this app Release history	
PATIENT HISTORY	In order to keep patient data private do not enter PHI directly into the			ory
	Showing trials specific to Country: United Kingdom × Trial Start Date: Ia			
APPS	Conditions: Adenocarcinoma × Age: 81 × Gender: Female × Biom	arkers: ALK negative × ROS1	negative × PD-L1 Weak Po	ositive ×
	Anatomical Location: Lung ×			
Clinical Trial Publication Guidelines	last updated on 3 Dec 2020 by Molecular Match	powered by XMolecularMatch	Refine results	Apply
	Start date: 28 June 2019 Last update: 25 November 2020	1-2-3-4	Locations	
	Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L)	Type Interventional Status Recruiting Source CTGOV	United Kingdom	

2) Overview of search results layout in NAVIFY Clinical Trial Match, including the search terms extracted from the patient record in NAVIFY Tumor Board.

TUMOR BOARDS PATIENTS	APPS			Q Imperia	I Study Roche	GE Health
Patel, Anushka		Patient and Disease Criteria from Tur	nor Board:			
male, 81 RN IGHI008		🔍 Age 🔳 Gender 🗨	Biomarkers	Tumor information	Stage	nelp & more
CANCER INFO		Genomic alterations				
Lung Adenocarcinoma	Clini	Refine Search Results:				æ
c 2 0 0	Add Ad	Location ①	Trial Phase ①	Trial Start Date	e	0
	Ааа Аа	Country	Phase 0	O any time		Q
PATIENT HISTORY	In order to		Phase 2	-	e years and upcoming years and upcoming	
	Showing tr	within Radius Unit	Phase 3 Phase 4	O last year	and upcoming	-
APPS	Conditions	Zip Code		-	nths and upcoming	re ×
	Anatomica		_	*		
Clinical Trial Publication Guidelines Match Search	last update	Show only trials in this organization Trial statuses				Apply
	Start date:	Enrolling				
	Last update Study of	Closed				-
	or Maint	Open				
App Launch Prefer	ences in I	NAVIFY Clinical Trial M	atch.	X		
	ences in I	NAVIFY Clinical Trial M	atch.	Q Imperia	Il Study Roche	GE Healt
UMOR BOARDS PATIENTS	APPS				Type Intervent	tional
UMOR BOARDS PATIENTS	APPS Metast	tatic Non-Small Ce	ll Lung Car	ncer		tional
UMOR BOARDS PATIENTS oggs, Joe e, 70 N IGHI005	APPS Metast Previo	tatic Non-Small Ce Jusly Treated With a	ll Lung Car an Anti-PD	ncer D-L1/PD-1	Type Intervent Status Recruitin	tional
UMOR BOARDS PATIENTS oggs, Joe ie, 70 N IGHI005 CANCER INFO Lung	APPS Metast Previo Antibo	tatic Non-Small Ce busly Treated With a ody and Platinum-C	ll Lung Car an Anti-PD	ncer D-L1/PD-1	Type Intervent Status Recruitin Source CTGOV	tional
UMOR BOARDS PATIENTS oggs, Joe le, 70 N IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma	APPS Metast Previo Antibo	tatic Non-Small Ce Jusly Treated With a	ll Lung Car an Anti-PD	ncer D-L1/PD-1	Type Intervent Status Recruitin Source CTGOV	tional
UMOR BOARDS PATIENTS Oggs, Joe le, 70 N IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma c 3 2 1 3 Stage 1	APPS Metast Previo Antibo	tatic Non-Small Ce busly Treated With a ody and Platinum-C	ll Lung Car an Anti-PD	ncer D-L1/PD-1	Type Intervent Status Recruitin Source CTGOV Drugs Cabozantinib	tional
UMOR BOARDS PATIENTS oggs, Joe le, 70 N IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma	APPS Metast Previo Antibo	tatic Non-Small Ce ously Treated With a ody and Platinum-C otherapy	ll Lung Car an Anti-PD Containing	ncer D-L1/PD-1	Type Intervent Status Recruitin Source CTGOV Drugs Cabozantinib Atezolizumab Docetaxel	ional g
PUMOR BOARDS PATIENTS Oggs, Joe le, 70 IN IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma C G G G G G G G G G G G G G G G G G G	APPS Metast Previo Antibo Chemo	tatic Non-Small Ce ously Treated With a ody and Platinum-C otherapy ction Eligibility Lo	ll Lung Car an Anti-PD Containing	ncer)-L1/PD-1	Type Intervent Status Recruitin Source CTGOV Drugs Cabozantinib Atezolizumab	ional g
CUMOR BOARDS PATIENTS Oggs, Joe le, 70 N IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma c	APPS Metast Previo Antibo Chemo Introduc Purpose	tatic Non-Small Celously Treated With a ody and Platinum-Cotherapy ction Eligibility Lo	Il Lung Car an Anti-PD Containing	ncer D-L1/PD-1 S	Type Intervent Status Recruitin Source CTGOV Drugs Cabozantinib Atezolizumab Docetaxel Pathway/Molecular	ional g
CUMOR BOARDS PATIENTS Oggs, Joe le, 70 N IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma c	APPS Metast Previo Antibo Chemo Introduc Purpose This is a Ph evaluate th	tatic Non-Small Ce busly Treated With a ody and Platinum-Co otherapy ction Eligibility Lo base III, multicenter, randomize the efficacy, safety, and pharmad	Il Lung Car an Anti-PD Containing ocations Ma d, open-label stud cokinetics of atezed	ncer D-L1/PD-1 S atch Explanation dy designed to olizumab given in	Type Intervent Status Recruitin Source CTGOV Drugs Cabozantinib Atezolizumab Docetaxel Pathway/Molecular Wild-Type ALK CD274	ional g
CUMOR BOARDS PATIENTS Oggs, Joe le, 70 N IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma c	APPS Metast Previo Antibo Chemo Introduc Purpose This is a Ph evaluate th combinatio	tatic Non-Small Ce busly Treated With a ody and Platinum-C otherapy ction Eligibility La hase III, multicenter, randomize the efficacy, safety, and pharmac on with cabozantinib compared	Il Lung Car an Anti-PD Containing ocations Ma d, open-label stud okinetics of atezed with docetaxel n	ncer D-L1/PD-1 S atch Explanation dy designed to olizumab given in monotherapy in	Type Intervent Status Recruitin Source CTGOV Drugs Cabozantinib Atezolizumab Docetaxel Pathway/Molecular Wild-Type ALK	ional g
CUMOR BOARDS PATIENTS Oggs, Joe le, 70 NN IGHI005 CANCER INFO Lung Metastatic Adenocarcinoma c 3 2 1a Stage !	APPS Metast Previo Antibo Chemo Introduc Purpose This is a Ph evaluate th combinatio patients wi	tatic Non-Small Ce busly Treated With a ody and Platinum-Co otherapy ction Eligibility Lo base III, multicenter, randomize the efficacy, safety, and pharmad	Il Lung Car an Anti-PD Containing d, open-label stud octions Ma d, open-label stud okinetics of ateze with docetaxel n ensitizing EGFR m	Accer D-L1/PD-1 S atch Explanation dy designed to olizumab given in monotherapy in nutation or ALK	Type Intervent Status Recruitin Source CTGOV Drugs Cabozantinib Atezolizumab Docetaxel Pathway/Molecular Wild-Type ALK CD274 Conditions	ional g

4) Information on each of the matching clinical trials is extracted from the relevant database(s) and presented in NAVIFY Clinical Trial Match.

TUMOR BOARDS PATIENTS	APPS	Q Impe	erial Study	GE Healthcare
Spring, Kathleen Female, 58 MRN IGHI010				help & more
CANCER INFO Lung Metastatic Adenocarcinoma	Clinical Trial Match			æ
c 4 2 1a	-"first			Q
PATIENT HISTORY	first-line the py			
APPS Clinical Trial Match Publication Search Guidelines	disease after first-line first line systemic treatment Swedish Medical Center- First Hill Genomic atterations: ско negative л р4и negative л			
	Showing results for: Biomarkers TTF1 positive Search instead for: Biomarkers <u>TTF1 positive</u> last updated on 3 Dec 2020 by Molecular Match	powered by XMolecularMatch	Refine results	Apply

5) Example of a participant adding their own search terms in NAVIFY Clinical Trial Match.